Inscrição na biblioteca: Guest
Critical Reviews™ in Oncogenesis

Publicou 4 edições por ano

ISSN Imprimir: 0893-9675

ISSN On-line: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

The Role of Metalloproteinases and Their Inhibitors in Hematological Disorders

Volume 7, Edição 3-4, 1996, pp. 205-226
DOI: 10.1615/CritRevOncog.v7.i3-4.40
Get accessGet access

RESUMO

The balance between the activities of matrix metalloproteinases (MMPs) and the tissue inhibitors of metalloproteinases (TIMPs) is an important control point during the turnover of the extracellular matrix. Previous studies have demonstrated that an uncontrolled rate of production of these proteins leads to various pathological conditions. Overexpression of MMPs by malignant cells can increase the invasive behavior of solid tumors and their metastatic potential. In an increasing number of reports, it has become evident that expression of MMPs and TIMPs is not restricted to solid tumors. Normal and malignant hematological cells also express these proteins and play a pivotal role in the hematological-cell physiology. In addition to modifying the extracellular matrix, MMPs and TIMPs exert other functions in hematological cells, including growth-factor activity, removal of cell-surface receptors, and autoimmunity. The goal of this review is to gather recent studies concerning the properties of MMPs and TIMPs in hematological cells, their regulation of gene expression, their cellular distribution, and their potential role in the pathogenesis of hematological disorders such as inflammation and neoplasia.

CITADO POR
  1. Basu Sanchita, Pathak Shresh, Pathak Sushil Kumar, Bhattacharyya Asima, Banerjee Anirban, Kundu Manikuntala, Basu Joyoti, Mycobacterium avium-induced matrix metalloproteinase-9 expression occurs in a cyclooxygenase-2-dependent manner and involves phosphorylation- and acetylation-dependent chromatin modification, Cellular Microbiology, 9, 12, 2007. Crossref

  2. Mysliwiec Angela G., Ornstein Deborah L., Matrix Metalloproteinases in Colorectal Cancer, Clinical Colorectal Cancer, 1, 4, 2002. Crossref

  3. Yu Jian-Bo, Zhang Ying-Chun, Yang Qun-Pei, Wang Xiao-Ling, Tang Yuan, Zhao Sha, Mo Xian-Ming, Liu Wei-Ping, Invasion-associated genes identified by gene expression profiling in extranodal natural killer/T-cell lymphoma, nasal type, Leukemia & Lymphoma, 54, 1, 2013. Crossref

  4. Remacle A., McCarthy K., Noël A., Maguire T., McDermott E., O'Higgins N., Foidart J.M., Duffy* M.J., High levels of TIMP-2 correlate with adverse prognosis in breast cancer, International Journal of Cancer, 89, 2, 2000. Crossref

  5. Albert J., Radomski A., Soop A., Sollevi A., Frostell C., Radomski M. W., Differential release of matrix metalloproteinase-9 and nitric oxide following infusion of endotoxin to human volunteers, Acta Anaesthesiologica Scandinavica, 47, 4, 2003. Crossref

  6. Rossi Lara, Ergen Aysegul V., Goodell Margaret A., TIMP-1 deficiency subverts cell-cycle dynamics in murine long-term HSCs, Blood, 117, 24, 2011. Crossref

  7. Suzuki Jun-ichi, Isobe Mitsuaki, Kawauchi Motohiro, Endoh Munemoto, Amano Jun, Takamoto Shinichi, Altered expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in acutely rejected myocardium and coronary arteriosclerosis in cardiac allografts of nonhuman primates, Transplant International, 13, 2, 2000. Crossref

  8. Tekabe Yared, Li Qing, Luma Joane, Weisenberger Drew, Sedlar Marija, Harja Evis, Narula Jagat, Johnson Lynne L., Noninvasive monitoring the biology of atherosclerotic plaque development with radiolabeled annexin V and matrix metalloproteinase inhibitor in spontaneous atherosclerotic mice, Journal of Nuclear Cardiology, 17, 6, 2010. Crossref

  9. Guedez Liliana, Stetler-Stevenson William G., The prognostic value of TIMP-1 in multiple myeloma, Leukemia Research, 34, 5, 2010. Crossref

  10. Heissig Beate, Ohki Makiko, Ishihara Makoto, Tashiro Yoshihiko, Nishida Chiemi, Gritli Ismael, Rosenkvist Jeanette, Hattori Koichi, Contribution of the fibrinolytic pathway to hematopoietic regeneration, Journal of Cellular Physiology, 221, 3, 2009. Crossref

  11. Gaudin Philippe, Trocmé Candice, Berthier Sylvie, Kieffer Sylvie, Boutonnat Jean, Lamy Christophe, Surla Anny, Garin Jérome, Morel Françoise, TIMP-1/MMP-9 imbalance in an EBV-immortalized B lymphocyte cellular model: evidence for TIMP-1 multifunctional properties, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1499, 1-2, 2000. Crossref

  12. Haviernik Peter, Diaz Maria T., Haviernikova Eleonora, Tse William, Stetler-Stevenson William G., Bunting Kevin D., Hematopoiesis in mice is extremely resilient to wide variation in TIMP/MMP balance, Blood Cells, Molecules, and Diseases, 41, 2, 2008. Crossref

  13. Guedez Liliana, McMarlin Andrew J., Kingma Douglas W., Bennett Teresa A., Stetler-Stevenson Maryalice, Stetler-Stevenson William G., Tissue Inhibitor of Metalloproteinase-1 Alters the Tumorigenicity of Burkitt’s Lymphoma via Divergent Effects on Tumor Growth and Angiogenesis, The American Journal of Pathology, 158, 4, 2001. Crossref

  14. Tapp Henri S., Radonjic Marijana, Kate Kemsley E., Thissen Uwe, Evaluation of multiple variate selection methods from a biological perspective: a nutrigenomics case study, Genes & Nutrition, 7, 3, 2012. Crossref

  15. Ayres-Silva Jackline de Paula, Manso Pedro Paulo de Abreu, Madeira Mariana Rietmann da Cunha, Pelajo-Machado Marcelo, Lenzi Henrique Leonel, Sequential morphological characteristics of murine fetal liver hematopoietic microenvironment in Swiss Webster mice, Cell and Tissue Research, 344, 3, 2011. Crossref

  16. Kossakowska Anna E., Urbanski Stefan J., Janowska-Wieczorek Anna, Matrix Metalloproteinases and Their Tissue Inhibitors - Expression, Role and Regulation in Human Malignant Non-Hodgkin's Lymphomas, Leukemia & Lymphoma, 39, 5-6, 2000. Crossref

  17. Maral Senem, Acar Muradiye, Balcik Ozlem Sahin, Uctepe Eyyup, Hatipoglu Omer Faruk, Akdeniz Derya, Altun Hatice Uludag, Kosar Ali, Gunduz Mehmet, Gunduz Esra, Matrix Metalloproteinases 2 and 9 Polymorphism in Patients With Myeloproliferative Diseases, Medicine, 94, 16, 2015. Crossref

  18. Weber Lutz W. D., Boll Meinrad, Stampfl Andreas, Hepatotoxicity and Mechanism of Action of Haloalkanes: Carbon Tetrachloride as a Toxicological Model, Critical Reviews in Toxicology, 33, 2, 2003. Crossref

  19. Hoffmann Ursula, Hoffmann Ursula, Bertsch Thomas, Hoffmann Ursula, Bertsch Thomas, Dvortsak Eszter, Liebetrau Claudia, Lang Siegfried, Liebe Volker, Huhle Guenter, Borggrefe Martin, Brueckmann Martina, Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: Prognostic value of TIMP-1 in severe sepsis, Scandinavian Journal of Infectious Diseases, 38, 10, 2006. Crossref

  20. Lush Richard M., Rudek Michelle A., Figg William D., Review of Three New Agents that Target Angiogenesis, Matrix Metalloproteinases, and Cyclin-Dependent Kinases, Cancer Control, 6, 5, 1999. Crossref

  21. Raychaudhuri Susri, Ghosh Satyabrata, Roy Anirban, Swarnakar Snehasikta, Protective Role of Black Tea Flavonoids Against Ethanol-Induced Gastropathy via Matrix Metalloproteinase Pathway, Indian Journal of Clinical Biochemistry, 34, 4, 2019. Crossref

  22. Noël Agnes, Albert Valerie, Bajou Khalid, Bisson Christele, Devy Laetitia, Frankenne Francis, Maquoi Erik, Masson Veronique, Sounni Nor-Eddine, Foidart Jean Michel, New Functions of Stromal Proteases and Their Inhibitors in Tumor Progression, Surgical Oncology Clinics of North America, 10, 2, 2001. Crossref

  23. Rudek Michelle A., Venitz Jürgen, Figg William D., Matrix Metalloproteinase Inhibitors: Do They Have a Place in Anticancer Therapy?, Pharmacotherapy, 22, 6, 2002. Crossref

  24. Kossakowska Anna E., Edwards Dylan R., Prusinkiewicz Christopher, Zhang Melissa C., Guo Dianlin, Urbanski Stefan J., Grogan Thomas, Marquez Leah A., Janowska-Wieczorek Anna, Interleukin-6 Regulation of Matrix Metalloproteinase (MMP-2 and MMP-9) and Tissue Inhibitor of Metalloproteinase (TIMP-1) Expression in Malignant Non-Hodgkin’s Lymphomas, Blood, 94, 6, 1999. Crossref

  25. Guedez Liliana, Courtemanch Laurel, Stetler-Stevenson Maryalice, Tissue Inhibitor of Metalloproteinase (TIMP)-1 Induces Differentiation and an Antiapoptotic Phenotype in Germinal Center B Cells, Blood, 92, 4, 1998. Crossref

  26. Guedez Liliana, Courtemanch Laurel, Stetler-Stevenson Maryalice, Tissue Inhibitor of Metalloproteinase (TIMP)-1 Induces Differentiation and an Antiapoptotic Phenotype in Germinal Center B Cells, Blood, 92, 4, 1998. Crossref

  27. Kossakowska Anna E., Edwards Dylan R., Prusinkiewicz Christopher, Zhang Melissa C., Guo Dianlin, Urbanski Stefan J., Grogan Thomas, Marquez Leah A., Janowska-Wieczorek Anna, Interleukin-6 Regulation of Matrix Metalloproteinase (MMP-2 and MMP-9) and Tissue Inhibitor of Metalloproteinase (TIMP-1) Expression in Malignant Non-Hodgkin’s Lymphomas, Blood, 94, 6, 1999. Crossref

  28. Vočka Michal, Langer Daniel, Fryba Vladimir, Petrtyl Jaromir, Hanus Tomas, Kalousova Marta, Zima Tomas, Petruzelka Lubos, Serum levels of TIMP-1 and MMP-7 as potential biomarkers in patients with metastatic colorectal cancer, The International Journal of Biological Markers, 34, 3, 2019. Crossref

  29. Guedez Liliana, Martinez Antonio, Zhao Shumei, Vivero Angelica, Pittaluga Stefania, Stetler-Stevenson Maryalice, Raffeld Mark, Stetler-Stevenson William G., Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors, Blood, 105, 4, 2005. Crossref

  30. Bini Alessandra, Wu Dan, Schnuer Jamie, Kudryk Bohdan J., Characterization of Stromelysin 1 (MMP-3), Matrilysin (MMP-7), and Membrane Type 1 Matrix Metalloproteinase (MT1-MMP) Derived Fibrin(ogen) Fragments D-Dimer and D-like Monomer:  NH2-Terminal Sequences of Late-Stage Digest Fragments, Biochemistry, 38, 42, 1999. Crossref

  31. Haviernik Peter, Lahoda Carisa, Bradley Heath L, Hawley Teresa S, Ramezani Ali, Hawley Robert G, Stetler-Stevenson Maryalice, Stetler-Stevenson William G, Bunting Kevin D, Tissue inhibitor of matrix metalloproteinase-1 overexpression in M1 myeloblasts impairs IL-6-induced differentiation, Oncogene, 23, 57, 2004. Crossref

  32. Yu X F, Yang C, Liang L H, Liu B, Zhou B, Li B, Han Z C, Inhibition of human leukemia xenograft in nude mice by adenovirus-mediated tissue inhibitor of metalloproteinase-3, Leukemia, 20, 1, 2006. Crossref

  33. FABER-ELMANN A, STHOEGER Z, TCHERNIACK A, DAYAN M, MOZES E, Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus, Clinical and Experimental Immunology, 127, 2, 2002. Crossref

  34. Takeshita S, Tokutomi T, Kawase H, Nakatani K, Tsujimoto H, Kawamura Y, Sekine I, Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease, Clinical and Experimental Immunology, 125, 2, 2001. Crossref

  35. Choi Naeun, Kim Sung-Min, Hong Kwan Soo, Cho Gyunggoo, Cho Jee-Hyun, Lee Chulhyun, Ryu Eun Kyoung, The use of the fusion protein RGD-HSA-TIMP2 as a tumor targeting imaging probe for SPECT and PET, Biomaterials, 32, 29, 2011. Crossref

  36. Guo Xiao-Kui, Zhao Wan-Qian, Kondo Chihiro, Shimojo Nagahiro, Yamashita Kyoko, Aoki Takanori, Hayakawa Taro, Tissue inhibitors of metalloproteinases-1 (TIMP-1) and -2(TIMP-2) are major serum factors that stimulate the TIMP-1 gene in human gingival fibroblasts, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1763, 3, 2006. Crossref

  37. Zhang Yahong, McCluskey Kevin, Fujii Karen, Wahl Larry M., Differential Regulation of Monocyte Matrix Metalloproteinase and TIMP-1 Production by TNF-α, Granulocyte-Macrophage CSF, and IL-1β Through Prostaglandin-Dependent and -Independent Mechanisms, The Journal of Immunology, 161, 6, 1998. Crossref

Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain